Abstract:Objective: Clinical-sonographic scoring systems combining clinical features and ultrasound imaging markers have been proposed for the screening of placenta accreta spectrum, but their usefulness in different settings remains limited. This study aimed to assess and compare different clinical-sonographic score systems applied from mid-pregnancy for the prenatal evaluation of patients at risk of placenta accreta spectrum at birth. Data sources: PubMed/MEDLINE, Google Scholar, and Embase were searched between October 1982 and October 2022 to identify eligible studies. Study eligibility criteria: Observational studies providing data on the use of a combined clinical-ultrasound score system applied from mid-pregnancy for the prenatal evaluation of placenta accreta spectrum were included. Methods: Study characteristics were evaluated by 2 independent reviewers using a predesigned protocol registered on PROSPERO (CRD42022332486). Heterogeneity among studies was analyzed with Cochran's Q-test and I2 statistics. Statistical heterogeneity was quantified by estimating the variance between the studies using I2 statistics. The area under the receiver operating characteristic curve of each score and their summary receiver operating characteristic curves were calculated with sensitivity and specificity, and the integrated score of the summaries of the receiver operating characteristic curves of all sonographic markers was calculated. Forest plots were used to develop the meta-analysis of each sonographic marker and for the integrated sonographic score. Results: Of 1028 articles reviewed, 12 cohorts and 2 case-control studies including 1630 patients screened for placenta accreta spectrum by clinical-ultrasound scores met the eligibility criteria. A diagnosis of placenta accreta spectrum was reported in 602 (36.9%) cases, for which 547 (90.9%) intraoperative findings and/or histopathologic data were described. A wide variation was observed among the studies in reported sensitivities and specificities and in thresholds used for the identification of patients with a high probability of placenta accreta spectrum at birth. The summaries of the areas under the curve of the individual sonographic scores ranged from 0.85 (the lowest) for subplacental hypervascularity to 0.91 for placental location in the lower uterine segment, myometrial thinning, and placental lacunae and 0.95 for the loss of clear zone. Only 4 studies included placental bulging in their sonographic score system, and therefore no meta-analysis for this score was performed. The integrated summary of the areas under the curve was 0.83 (95% confidence interval, 79-0.86). Forest plot analysis revealed integrated sensitivities and specificities of 0.68 (95% confidence interval, 0.53-0.80) and 0.88 (95% confidence interval, 0.68-0.96), respectively. Conclusion: Clinical-sonographic score systems can contribute to the prenatal screening of patients at risk of placenta accreta spectrum at birth. Although we included multiple sonographic studies conducted during the mid-pregnancy period, standardized evaluation should be performed not only with strict ultrasound criteria for the placental position, mid third trimester gestational age at examination, and sonographic markers associated with PAS. Numeric sensitivities, specificities, NPVs, PPV, LR-, and LR+ should be recorded prospectively to assess their accuracy in different set-ups and PTP should be verified at delivery. The variables recommended for most predictive screening are: loss of clear zone underneath the placental bed, placentation in the LUS, and placenta lacunae.

EP16.51: Prenatal diagnosis accuracy for placenta accreta spectrum using magnetic resonance imaging: a systematic review and meta‐analysis

Diffusion MRI Based Myometrium Tractography for Detection of Placenta Accreta Spectrum Disorder

Ultrasound And Mri Accordance And Features In The Prenatal Diagnosis Of Placenta Accreta

Instrumental Diagnosis of Placenta Accreta and Obstetric and Perinatal Outcomes: Literature Review and Observational Study

Role of magnetic resonance imaging in the diagnosis of placenta accreta

Accuracy of MRI-Based Radiomics in Diagnosis of Placental Accreta Spectrum: A PRISMA Systematic Review and Meta-Analysis

Magnetic resonance imaging improves diagnosis of placenta accreta spectrum requiring hysterectomy compared to ultrasound

The Role of Ultrasonography and Magnetic Resonance Imaging in the Diagnosis of the Adherent Placenta: An Observational Study

EP16.54: Antenatal ultrasound and MR evaluation of placenta accreta spectrum disorders: clinical correlation done!

EP16.29: Comparative analysis of ultrasound and MRI in diagnosis of placenta accreta spectrum

Diagnostic accuracy of magnetic resonance imaging to predict peripartum hysterectomy and neonatal mortality in total placenta previa: A retrospective cohort study

EP16.06: Ultrasound dilemmas: the diagnostic challenge in detecting posterior placenta accreta

EP16.12: Accuracy of antenatal ultrasound evaluation of the placental pathologies using superb microvascular imaging

Application of Color Doppler Ultrasound Combined with Magnetic Resonance Imaging in Placenta Accreta

Prediction of placenta accreta spectrum in patients with placenta previa using clinical risk factors, ultrasound and magnetic resonance imaging findings

The predictive value of conventional magnetic resonance imaging combined with intravoxel incoherent motion parameters for evaluating maternal and neonatal clinical outcomes in patients with placenta accreta spectrum disorders

Assessment of the Massive Hemorrhage in Placenta Accreta Spectrum with Magnetic Resonance Imaging.

Placental volume as a novel sign for identifying placenta accreta spectrum in pregnancies with complete placenta previa

Placenta Accreta: A Spectrum of Predictable Risk, Diagnosis, and Morbidity

Clinical-sonographic scores for the screening of placenta accreta spectrum: a systematic review and meta-analysis

What We Know about Placenta Accreta Spectrum (PAS)